Cubist Pharmaceuticals, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products for the anti-infective market primarily in the United States. It offers Cubicin, an antibiotic from a class of antiinfectives called lipopeptides, for the treatment of complicated skin and skin structure infections, and for other blood-stream infections. The company’s research and development programs include lipopeptide programs, which are concentrated on the candidates that have the gram-positive antimicrobial spectrum of daptomycin and efficacy in the lung, as well as lipopeptide candidates with efficacy against gram-negative bacteria,...